These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 27988420

  • 1. Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M.
    J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
    [Abstract] [Full Text] [Related]

  • 2. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS.
    Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
    [Abstract] [Full Text] [Related]

  • 3. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
    Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, Ceballos KM, Jang D, Chernesky M, Franco EL, Ogilvie GS, Coldman AJ, Krajden M.
    J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
    [Abstract] [Full Text] [Related]

  • 4. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A, Brucker S, Sasieni P.
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
    Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS.
    Int J Cancer; 2011 Aug 01; 129(3):691-701. PubMed ID: 20941740
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T, Neis KJ, Castanon A, Landy R, Holz B, Woll-Herrmann A, Iftner A, Staebler A, Wallwiener D, Hann von Weyhern C, Neis F, Haedicke-Jarboui J, Martus P, Brucker S, Henes M, Sasieni P.
    J Clin Microbiol; 2019 Jan 01; 57(1):. PubMed ID: 30355760
    [Abstract] [Full Text] [Related]

  • 7. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
    Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N.
    J Clin Microbiol; 2011 Mar 01; 49(3):1071-6. PubMed ID: 21191046
    [Abstract] [Full Text] [Related]

  • 8. Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.
    Zhang J, Liu G, Yang D, Cui X, Wang C, Wang D, Piao H.
    Front Cell Infect Microbiol; 2024 Mar 01; 14():1428071. PubMed ID: 39268482
    [Abstract] [Full Text] [Related]

  • 9. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
    Castle PE, Eaton B, Reid J, Getman D, Dockter J.
    J Clin Microbiol; 2015 Apr 01; 53(4):1277-81. PubMed ID: 25653409
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M.
    BMC Cancer; 2015 Dec 16; 15():968. PubMed ID: 26674353
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.
    Vaccine; 2012 Nov 20; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, Lee M, Gentile L, Gondara L, Elwood-Martin R, Peacock S, Stuart G, Franco EL, Coldman AJ.
    Int J Cancer; 2017 Jan 15; 140(2):440-448. PubMed ID: 27685757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
    Reid JL, Wright TC, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D, Giachetti C.
    Am J Clin Pathol; 2015 Sep 15; 144(3):473-83. PubMed ID: 26276778
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.